Glenmark and Helsinn Group’s exclusive licensing deal for launch of Akynzeo in India and Nepal

Glenmark Pharmaceuticals Ltd, a research-led global integrated pharmaceutical company, and Helsinn Group (“Helsinn”), a Swiss pharmaceutical group focused on building quality cancer care products, are pleased to announce that they have entered into an exclusive licensing agreement to introduce Akynzeo in India and Nepal.

Akynzeo, an oral fixed combination of netupitant 300mg and palonosetron 0.5mg in capsule form, is used for prevention of chemotherapy-induced nausea and vomiting (CINV). The licensing agreement with Glenmark for Akynzeo represents Helsinn’s first such agreement in India. Glenmark will have exclusive marketing rights for Akynzeo in India and Nepal.

Glenmark has received marketing approval for Akynzeo from the Central Drugs Standard Control Organization (CDSCO).

Akynzeo is the first and only combination anti-emetic prophylaxis with high complete response rates for five days in cancer chemotherapy treated patients, having demonstrated 90% complete response rates through five days compared to 77% for oral palonosetron in patients receiving HEC cisplatin-based chemotherapy. It has been included among the recommended options in the MASCC/ESMO, ASCO and NCCN antiemesis guidelines. Delayed nausea is still a problem for up to 82% of patients receiving MEC (Moderately Emetogenic Chemotherapy) and HEC (Highly Emetogenic Chemotherapy), representing a significant unmet medical need.

Akynzeo was developed by Helsinn and it is currently marketed in EU, in the US, and several other leading markets of the world. 

Key driver for the deal:

• Akynzeo will add into portfolio of the Glenmark. Glenmark already has strong presence in oncology segment.
• At the same time, for Helsinn Group is a win – win collaboration as they will able to sale the product through Glenmark’s strong marketing presence in India and Nepal.